Compare BIO-TECHNE Corp (TECH) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Zillow Group Inc Class A — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.33B), while Zillow Group Inc Class A trades at $32.92 (market cap $7.26B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| TECH | ZG | |
|---|---|---|
Market Cap | $11.33B | $7.26B |
Sector | Health | Media |
52-Week High | $72.48 | $86.76 |
52-Week Low | $43.31 | $29.14 |
Enterprise Value | $11.35B | $7.14B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Zillow Group (ZG) trades at $33.03, down 6.48% over 24 hours, reflecting bearish technical signals amid a challenging housing market. The stock shows mixed fundamentals with a high P/E ratio of 143.57 but improving revenue growth to $2.58B in 2025 and a return to net profitability. Recent news highlights Zillow's shift to an integrated transaction platform and a settled FTC lawsuit, while analyst consensus remains cautiously optimistic with a $47.56 price target.
The outlook balances growth potential from Zillow's monetization strategy against near-term headwinds like elevated interest rates dampening home sales. Risks include execution challenges in the business model transition and competitive pressures, but institutional buying and earnings beats suggest underlying strength. Investors should weigh the high valuation against improving cash flow and market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
